Sweden

Sweden's primary regulatory authority for health products is the Swedish Medical Products Agency (Läkemedelsverket, MPA), operating under the Ministry of Health and Social Affairs. As a European Union member state, Sweden follows EU-wide regulatory frameworks: pharmaceuticals are governed by Directive 2001/83/EC and Regulation (EC) No 726/2004, medical devices by the EU Medical Device Regulation (MDR, 2017/745) and In Vitro Diagnostic Regulation (IVDR, 2017/746), and digital health tools are increasingly assessed under EU guidance on Software as a Medical Device (SaMD). Centralized marketing authorizations granted by the European Medicines Agency (EMA) are automatically valid in Sweden, while national and decentralized procedures are coordinated through the MPA. The MPA also serves as a Notified Body-adjacent authority, overseeing market surveillance and post-market monitoring of devices.

For submissions following the centralized EMA pathway, the standard CTD (Common Technical Document) format is required, with timelines governed by EU procedures (e.g., 210 days for standard, 150 days for accelerated review). National procedures handled directly by the MPA follow similar CTD standards with Swedish-language labeling requirements for patient-facing materials. A local EU-based authorized representative is mandatory for non-EU manufacturers. Sweden has been active in implementing the EU MDR and IVDR transition requirements and participates in the European database for medical devices (EUDAMED). Recent reforms include tighter post-market clinical follow-up requirements under MDR, enhanced pharmacovigilance obligations under the Falsified Medicines Directive, and growing regulatory guidance for AI-based and digital health products aligned with the EU AI Act framework.

Public procurement of health products in Sweden is primarily managed at two levels: national and regional. The Dental and Pharmaceutical Benefits Agency (Tandvards- och lakemedelsformansverket, TLV) is responsible for reimbursement decisions and pricing assessments for pharmaceuticals and certain medical devices, applying health technology assessment (HTA) criteria based on cost-effectiveness, need, and solidarity principles. The 21 county councils and regions (landsting/regioner) are largely autonomous in procuring medical devices, diagnostics, and hospital pharmaceuticals, typically through coordinated procurement via regional consortia such as Samverkan Upphandling (SKR Kommentus) and the National Government Service Center. The Public Procurement Act (LOU, lag 2016:1145) governs all public tenders, mandating open competitive bidding, transparency, and non-discrimination. National pharmaceutical agreements for subsidized outpatient drugs are negotiated between the MPA, TLV, and manufacturers, with reimbursement listed on the pharmaceutical benefits schedule (hogkostnadsskyddet).

The private healthcare sector in Sweden, while smaller than the public sector, plays a meaningful role in diagnostics, dental care, and specialist services, and procures health products through direct commercial channels outside LOU constraints. Sweden does not rely significantly on donor-funded procurement mechanisms such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income country and a major donor to such programs rather than a recipient. There are no explicit local manufacturing preference policies in Swedish public procurement; however, supply chain resilience and domestic production capacity have gained increased policy attention following post-pandemic strategic reviews, with the government exploring incentives for regional pharmaceutical manufacturing in alignment with EU pharmaceutical strategy priorities.